Indacaterol/mometasone
Combination of | |
---|---|
Indacaterol | Beta-2 adrenergic receptor agonist |
Mometasone | Corticosteroid |
Clinical data | |
Trade names | Atectura Breezhaler, Bemrist Breezhaler |
Other names | QMF149, IND/MF |
License data | |
Inhalation | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a
beta2 agonists.[2]
The most common side effects include worsening of
nasopharyngitis (inflammation in the nose and throat).[2] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[2] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,[2] and in Japan in June 2020.[6]
References
- ^ "Regulatory Decision Summary - Atectura Breezhaler". Health Canada. 23 October 2014. Retrieved 7 June 2022.
- ^ a b c d e "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Bemrist Breezhaler EPAR". European Medicines Agency. 24 March 2020. Retrieved 4 March 2023.
- ^ "Atectura Breezhaler Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "Bemrist Breezhaler Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Archived from the original on 26 July 2020. Retrieved 25 July 2020.
External links
- "Indacaterol mixture with mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.